Abstract
Psoriasis is one of the most common inflammatory skin diseases. The mild form of psoriasis is usually treated with topical medications and phototherapy, whereas conventional systemic therapies, including retinoids, cyclosporine and methotrexate, are used for the treatment of moderate-to-severe psoriasis. The therapeutic approach has been revolutionized over the past decade by the introduction of biologic agents or ‘small molecules’ that have been proven to have striking clinical efficacy. This review highlights the most effective topical antipsoriatic treatments, focusing on emerging promising topical drugs that are currently being tested in ongoing clinical trials.
Financial & competing interests disclosure
S Chimenti has been a speaker and consultant for Pfizer, Merck Sharp and Dohme, Abbott, Janssen-Cilag, Novartis and Leo-Pharma. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.